Correction "Smart drugs for cognitive enhancement: ethical and pragmatic considerations in the era of cosmetic neurology" [J Med Ethics 2009;35:611-615 DOI: 10.1136/jme.2009.030882];Smart drugs for cognitive enhancement: Ethical and pragmatic considerations in the era of cosmetic neurology

Journal of Medical Ethics

Volumn 35, Issue 10, 2009, Pages 611-615

  Cakic, V ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72449153396     PISSN: 03066800     EISSN: 14734257     Source Type: Journal    
DOI: 10.1136/jme.2007.030882corr1     Document Type: Erratum

References (51)

1. Le Strange R. A history of herbal plants. London: Angus and Robertson, 1977.
2. Chatterjee A. The promise and predicament of cosmetic neurology. J Med Ethics 2006;32:110-13.
3. Chatterjee A. Cosmetic neurology: the controversy over enhancing movement, mentation, and mood. Neurology 2004;63:968-74.
4. Szalavitz M. Popping smart pills: the case for cognitive enhancement. Time 6 January 2009. http://www.time.com/time/health/article/0,8599,1869435,00.html (accessed Jul 2009).
5. Fallik D. Improve my mind, please. Philadelphia Inquirer 2005 March:D1.
6. Douglas K, George A, Holmes B, et al. 11 Steps to a better brain. New Scientist 28 May 2005. http://www.newscientist.com/article/mg18625011.900-11-steps-to-a-better-brain.html (accessed Jul 2009).
7. Kher U. Can you find concentration in a bottle? Time 8 January 2006. http://www.time.com/time/magazine/article/0,9171,1147202,00.html (accessed Jul 2009).
8. Lawton G. Get ready for 24-hour living. New Scientist 18 February 2006. http://www.newscientist.com/article/mg18925391.300-get-ready-for-24hour-living.html (accessed Jul 2009).
9. Dekkers W, Rikkert MO. Memory enhancing drugs and Alzheimer's disease: enhancing the self or preventing the loss of it? Med Health Care Philos 2007;10:141-51.
10. Lanni C, Lenzken SC, Pascale A, et al. Cognition enhancers between treating and doping the mind. Pharmacol Res 2008;57:196-213.
11. de Jongh R, Bolt I, Schermer M, et al. Botox for the brain: enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neurosci Biobehav Rev 2008;32:760-76.
12. Farah MJ. Emerging ethical issues in neuroscience. Nat Neurosci 2002;5:1123-9.
13. Rose SPR. 'Smart drugs': do they work? Are they ethical? Will they be legal? Nat Rev Neurosci 2002;3:975-9.
14. Whitehouse PJ, Juengst E, Mehlman M, et al. Enhancing cognition in the intellectually intact. Hastings Cent Rep 1997;27:14-22.
15. Turner DC, Sahakian BJ. The cognition-enhanced classroom. In: Zonneveld L, Dijstelbloem H, Ringoir D, eds. Reshaping the human condition: exploring human enhancment. The Hague: Rathenau Institute, 2008:107-13.
16. Sheridan K, Zinchenko E, Gardner H. Neuroethics in education. In: Illes J, ed. Neuroethics in the 21st century: defining the issues in theory, practice, and policy. New York: Oxford University Press, 2005:265-75.
17. Levy N. The presumption against direct manipulation. In: Levy N, ed. Neuroethics: challenges for the 21st century. Cambridge: Cambridge University Press, 2007:88-135.
18. Schermer M. On the argument that enhancement is "cheating". J Med Ethics 2008;34:85-8.
19. McCabe SE, Knight JR, Teter CJ, et al. Non-medical use of prescription stimulants among US college students: prevalence and correlates from a national survey. Addiction 2005;99:96-106.
20. Murray TH. The coercive power of drugs in sports. Hastings Cent Rep 1983;13:24-30.
21. Smith ACT, Stewart B. Drug policy in sport: hidden assumptions and inherent contradictions. Drug Alcohol Rev 2008;27:123-9.
22. Foddy B, Savulescu J. Ethics of performance enhancement in sport: drugs and gene doping. In: Ashcroft RE, Dawson A, Draper H, McMillan JR, eds. Principles in health care ethics. New York: John Wiley and Sons, 2007:511-19.
23. Loland S. Fair play in sport: a moral norm system. London: Routledge, 2002.
24. Kayser B, Mauron A, Miah A. Current anti-doping policy: a critical appraisal. BMC Med Ethics 2007;8:1-10.
25. Rohde TE, Thompson LA. Predicting academic achievement with cognitive ability. Intelligence 2007;35:83-92.
26. Devlin B, Daniels M, Roeder K. The heritability of IQ. Nature 2001;388:468-70.
27. Attewell P, Battle J. Home computers and school performance. Inf Soc 1999;15:1-10.
28. Bloom BS. The 2 sigma problem: the search for methods of group instruction as effective as one-to-one tutoring. Educ Res 1984;13:4-16.
29. Glewwe P, Jacoby HG, King EM. Early childhood nutrition and academic achievement: a longitudinal analysis. J Public Econ 2001;81:345-68.
30. Randall DC, Shneerson JM, File SE. Cognitive effects of modafinil in student volunteers may depend on IQ. Pharmacol Biochem Behav 2005;82:133-9.
31. Morgan WJ. Fair is fair, or is it?: a moral consideration of the doping wars in American sport. Sport Soc 2006;9:177-98.
32. Rabinowicz V. Athletes and drugs: a separate pace? Psychol Today 1992;25:52-3.
33. Degrazia D. Prozac, enhancement, and self-creation. Hastings Cent Rep 2000;30:34-40.
34. Brice C, Smith A. The effects of caffeine on simulated driving, subjective alertness and sustained attention. Hum Psychopharmacol Clin Exp 2001;16:523-31.
35. Diller LH. The run on Ritalin: attention deficit disorder and stimulant treatment in the 1990s. Hastings Cent Rep 1996;26:12-18.
36. Graff Low K, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med 2002;7:283-7.
37. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006;26:1501-10.
38. McKenzie K, Schweitzer R. Who succeeds at university? Factors predicting academic performance in first year Australian university students. Higher Educ Res Dev 2001;20:21-33.
39. World Anti-Doping Agency. World-anti-doping code. Montreal, Canada: World Anti-Doping Agency, 2003.
40. Thiblin I, Petersson A. Pharmacoepidemiology of anabolic androgenic steroids: a review. Fund Clin Pharmacol 2004;19:27-44.
41. Burke LM. Caffeine and sports performance. Appl Physiol Nutr Metab 2008;33:1319-34.
42. Leonard BE, McCartan D, White J, et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol Clin Exp 2004;19:151-80.
43. Russo A, Borrelli F. Bacopa monniera, a reputed nootropic plant: an overview. Phytomedicine 2005;12:305-17.
44. Jenner P, Zeng B-Y, Smith LA, et al. Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res 2000;133:178-88.
45. Tang Y-P, Wang H, Feng R, et al. Differential effects of enrichment on learning and memory function in NR2B transgenic mice. Neuropharmacology 2001;41:779-90.
46. Tang Y, Shimizu E, Tsien JZ. Do 'smart'mice feel more pain, or are they just better learners? Nat Neurosci 2001;4:453.
47. Warren OJ, Leff DR, Athanasiou T, et al. The neurocognitive enhancement of surgeons: an ethical perspective. J Surg Res 2009;152:167-72.
48. Haugen KK. The performance-enhancing drug game. J Sports Econ 2004;5:67-86.
49. Savulescu J, Foddy B, Clayton M. Why we should allow performance enhancing drugs in sport. Br J Sports Med 2004;38:666-70.
50. Cheshire WP. Drugs for enhancing cognition and their ethical implications: a hot new cup of tea. Expert Rev Neurother 2006;6:263-6.
51. Kenny DT, Faunce G. Effects of academic coaching on elementary and secondary school students. J Educ Res 2004;98:115-26.